Quarterly report [Sections 13 or 15(d)]

LICENSES ACQUIRED (Details)

v3.26.1
LICENSES ACQUIRED (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Nov. 11, 2024
Jun. 29, 2021
Dec. 31, 2024
Apr. 30, 2024
Jan. 31, 2022
Mar. 31, 2021
Jul. 31, 2020
Jun. 30, 2026
Jun. 30, 2026
Assets and Licenses Acquired                  
Total other revenues               $ 671 $ 711
Amzeeq                  
Assets and Licenses Acquired                  
Percentage of license         4.00%        
Zilxi                  
Assets and Licenses Acquired                  
Percentage of license         1.50%        
Emrosi Agreement                  
Assets and Licenses Acquired                  
Total Upfront payment   $ 10,000              
Upfront payment upon execution       $ 3,000          
Remaining upfront payment     $ 15,000            
Transformation of ownership and all assets of milestone payments   15,000              
Threshold additional contingent regulatory and commercial milestone payments payable   $ 150,000              
Percentage of reduction in royalty upon launching of competitor products   50.00%              
Emrosi Agreement | Minimum                  
Assets and Licenses Acquired                  
Percentage of royalties payable on net sales   10.00%              
Emrosi Agreement | Maximum                  
Assets and Licenses Acquired                  
Percentage of royalties payable on net sales   14.00%              
Asset purchase agreement | Qbrexza                  
Assets and Licenses Acquired                  
Age of patients           9 years      
Asset purchase agreement | Royalty payment percentage for first two years | Qbrexza                  
Assets and Licenses Acquired                  
Period of royalty payments           2 years      
Asset purchase agreement | Minimum | Royalty payment percentage for first two years | Qbrexza                  
Assets and Licenses Acquired                  
Percent of royalty payments           30.00%      
Asset purchase agreement | Minimum | Royalty payment percentage for thereafter | Qbrexza                  
Assets and Licenses Acquired                  
Percent of royalty payments           12.00%      
Asset purchase agreement | Maximum | Royalty payment percentage for first two years | Qbrexza                  
Assets and Licenses Acquired                  
Percent of royalty payments           40.00%      
Asset purchase agreement | Maximum | Royalty payment percentage for thereafter | Qbrexza                  
Assets and Licenses Acquired                  
Percent of royalty payments           19.00%      
Asset purchase agreement | Eli Lilly and Company | Qbrexza                  
Assets and Licenses Acquired                  
Upfront fees           $ 12,500      
Milestone payments payable           $ 144,000      
License and supply agreement With DRL | Accutane                  
Assets and Licenses Acquired                  
Amount of expense agreed to pay under the agreement             $ 5,000    
Contingent amount payable             $ 17,000    
Term of accutane             10 years    
Termination accutane agreement period             180 days    
Cutia License Agreement | Amzeeq                  
Assets and Licenses Acquired                  
Milestone payment $ 1,000                
Total other revenues $ 1,000                
VYNE APA                  
Assets and Licenses Acquired                  
Total Upfront payment         $ 450,000        
Upfront payment upon execution         5,000        
Upfront fees         20,000        
VYNE APA | Amzeeq | First year anniversary                  
Assets and Licenses Acquired                  
Net sales         100,000        
Amount of expense paid under the agreement         10,000        
VYNE APA | Amzeeq | Second year anniversary                  
Assets and Licenses Acquired                  
Net sales         200,000        
Amount of expense paid under the agreement         20,000        
VYNE APA | Amzeeq | Third year anniversary                  
Assets and Licenses Acquired                  
Net sales         300,000        
Amount of expense paid under the agreement         30,000        
VYNE APA | Amzeeq | Fourth year anniversary                  
Assets and Licenses Acquired                  
Net sales         400,000        
Amount of expense paid under the agreement         40,000        
VYNE APA | Amzeeq | Fifth year anniversary                  
Assets and Licenses Acquired                  
Net sales         500,000        
Amount of expense paid under the agreement         50,000        
VYNE APA | Zilxi | First year anniversary                  
Assets and Licenses Acquired                  
Net sales         100,000        
Amount of expense paid under the agreement         10,000        
VYNE APA | Zilxi | Second year anniversary                  
Assets and Licenses Acquired                  
Net sales         200,000        
Amount of expense paid under the agreement         20,000        
VYNE APA | Zilxi | Third year anniversary                  
Assets and Licenses Acquired                  
Net sales         300,000        
Amount of expense paid under the agreement         30,000        
VYNE APA | Zilxi | Fourth year anniversary                  
Assets and Licenses Acquired                  
Net sales         400,000        
Amount of expense paid under the agreement         40,000        
VYNE APA | Zilxi | Fifth year anniversary                  
Assets and Licenses Acquired                  
Net sales         500,000        
Amount of expense paid under the agreement         $ 50,000